Innovation and firm size in the pharmaceutical industry Online publication date: Fri, 18-Aug-2006
by Roxana Bobulescu, Celine Soulas
International Journal of Business Environment (IJBE), Vol. 1, No. 2, 2006
Abstract: The paper explains the main features of the relationship between firm size and innovativeness in the pharmaceutical industry. As the biotechnological paradigm is progressively replacing the chemical one, the biotech start-ups are the principal engine of R&D activity. They discover new molecules and impulse drug innovation. Still, big pharmaceutical companies (big pharmas) have some advantages, such as benefiting from higher funds to support development of new drugs, scale and scope economies in R&D. Partnerships between small and big firms are developed on a win-win basis. Consequently, the size of the firm is a moving target. Innovation is to be linked with industrial, technological networks. Small firms are cooperating and so increasing returns to scale may appear at the level of the research networks, strategic alliances or bio-clusters. Industrial policies stimulating innovation as a competitive edge should then concentrate on creating strong incentives for small firms to cooperate.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business Environment (IJBE):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook